EAS Independent Consultants Robin Guy and attorney Marc Ullman, Of Counsel with Rivkin Radler, will discuss CBD’s Uphill Battle to Answer FDA’s Safety Concerns in an IFT webinar covering expectations for FDA requirements to demonstrate safety through toxicology studies in support of filing a GRAS submission. If you are operating in the CBD space, it is imperative to understand the requirements of GRAS as well as how to develop a roadmap to a future successful FDA submission. Join EAS and IFT on May 20, 2020 at 11am eastern.
Posted in Cannabis, EAS in Action.